Incretin Agents Do Not Decrease Fracture Risk in Patients With Type-2 Diabetes April 1, 2015 By Chris Berrie MILAN, Italy – April 1, 2015 -- Incretin agents are not associated with decreased fracture risk in patients with type-2 diabetes, according to results from a meta-analysis of observational studies presented at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (WCO). There is also no variation in fracture risk with increasing cumulative doses of incretin agents, stated lead investigator Annemariek Driessen, PhD, Maastricht UMC, Maastricht, The Netherlands, speaking here on March 27.
The team performed a cohort study that used 2007 to 2012 data from the United Kingdom-based Clinical Practice Research Datalink (CPRD) -- the largest primary-care database available. This included users of DPP-4 inhibitors or GLP-1 receptor agonists (n = 22,510); Dr.…
